This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Cardiovascular Systems 미래 성장

Future 기준 확인 1/6

주요 정보

35.4%

수익 성장률

34.2%

EPS 성장률

Medical Equipment 수익 성장	12.7%
매출 성장률	11.1%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	09 Feb 2023

최근 미래 성장 업데이트

Recent updates

We're Not Very Worried About Cardiovascular Systems' (NASDAQ:CSII) Cash Burn Rate

Feb 03

We're Hopeful That Cardiovascular Systems (NASDAQ:CSII) Will Use Its Cash Wisely

Oct 12

Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates

Aug 03

Here's Why Cardiovascular Systems, Inc.'s (NASDAQ:CSII) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 05

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 36%?

Oct 09

At US$36.59, Is It Time To Put Cardiovascular Systems, Inc. (NASDAQ:CSII) On Your Watch List?

Sep 18

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 28%?

Jun 24

Is Now The Time To Look At Buying Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Jun 03

We're Interested To See How Cardiovascular Systems (NASDAQ:CSII) Uses Its Cash Hoard To Grow

Apr 29

Should You Take Comfort From Insider Transactions At Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Mar 17

Cardiovascular Systems (NASDAQ:CSII) Shareholders Have Enjoyed A Whopping 399% Share Price Gain

Feb 10

Cardiovascular Systems misses on revenue

Feb 03

Need To Know: Cardiovascular Systems, Inc. (NASDAQ:CSII) Insiders Have Been Selling Shares

Dec 11

Cardiovascular Systems, Inc. 2021 Q1 - Results - Earnings Call Presentation

Nov 06

수익 및 매출 성장 예측

NasdaqGS:CSII - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2025	321	-12	N/A	N/A	2
6/30/2024	283	-19	N/A	N/A	6
6/30/2023	257	-27	N/A	N/A	6
12/31/2022	240	-38	-34	-29	N/A
9/30/2022	238	-39	-31	-27	N/A
6/30/2022	236	-37	-28	-24	N/A
3/31/2022	245	-33	-17	-13	N/A
12/31/2021	252	-29	-17	-13	N/A
9/30/2021	257	-20	-13	-10	N/A
6/30/2021	259	-13	-5	-1	N/A
3/31/2021	231	-23	-18	-14	N/A
12/31/2020	228	-20	-16	-11	N/A
9/30/2020	233	-24	-14	-9	N/A
6/30/2020	237	-27	-17	-13	N/A
3/31/2020	262	-11	0	4	N/A
12/31/2019	264	-7	1	5	N/A
9/30/2019	256	-3	2	6	N/A
6/30/2019	248	0	7	10	N/A
3/31/2019	239	2	9	13	N/A
12/31/2018	231	2	11	14	N/A
9/30/2018	224	1	8	11	N/A
6/30/2018	217	2	7	10	N/A
3/31/2018	211	-1	2	5	N/A
12/31/2017	207	-3	2	5	N/A
9/30/2017	205	-2	17	19	N/A
6/30/2017	205	-2	18	20	N/A
3/31/2017	199	-7	11	13	N/A
12/31/2016	191	-28	6	8	N/A
9/30/2016	183	-45	N/A	-21	N/A
6/30/2016	177	-56	N/A	-24	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CSII 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CSII 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CSII 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CSII 의 수익(연간 11.1% ) US 시장( 8.2% 보다 빠르게 성장할 것으로 예상됩니다. 8.2% 연간).

고성장 수익: CSII 의 수익(연간 11.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CSII 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2023/04/27 01:03
장 마감 주가	2023/04/27 00:00
수익	2022/12/31
연간 수익	2022/06/30

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Cardiovascular Systems, Inc. 20 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Nathan Weinstein	Aegis Capital Corporation
Lawrence Neibor	Baird
Matt Miksic	Barclays

This company has been acquired

Cardiovascular Systems 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Price target decreased to US$21.20

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Year Ending June 30, 2023

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Year Ending June 30, 2023

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Price target decreased to US$23.50

Consensus revenue estimates fall by 10%

Recent updates

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.

We're Not Very Worried About Cardiovascular Systems' (NASDAQ:CSII) Cash Burn Rate

Cardiovascular Systems, Inc. to Report Q2, 2023 Results on Feb 09, 2023

Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study

Price target decreased to US$21.20

Insufficient new directors

First quarter 2023 earnings: EPS misses analyst expectations

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Year Ending June 30, 2023

Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems

Cardiovascular Systems, Inc. to Report Q1, 2023 Results on Nov 03, 2022

We're Hopeful That Cardiovascular Systems (NASDAQ:CSII) Will Use Its Cash Wisely

Cardiovascular Systems, Inc., Annual General Meeting, Nov 08, 2022

Full year 2022 earnings: EPS misses analyst expectations

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Year Ending June 30, 2023

Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates

Cardiovascular Systems, Inc. to Report Q4, 2022 Results on Aug 02, 2022

Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from Russell 2000 Growth-Defensive Index

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Price target decreased to US$23.50

Cardiovascular Systems, Inc. to Report Q3, 2022 Results on May 04, 2022

Cardiovascular Systems, Inc. Announces Ryan Egeland Employment Would End as Chief Medical Officer

Consensus revenue estimates fall by 10%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fiscal Year Ending June 30, 2022

Cardiovascular Systems, Inc. Along with Orbusneich Medical Company Ltd, Announces FDA PMA Approval of Orbusneich’s Scoreflex®NC Scoring Percutaneous Transluminal Coronary Angioplasty Catheter

Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery Diseases

No longer forecast to breakeven

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.054 loss in 1Q 2021)

Price target decreased to US$41.50

Here's Why Cardiovascular Systems, Inc.'s (NASDAQ:CSII) CEO Compensation Is The Least Of Shareholders' Concerns

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 36%?

Cardiovascular Systems, Inc. Announces First Patient Treated with ViperCross Peripheral Support Catheter

At US$36.59, Is It Time To Put Cardiovascular Systems, Inc. (NASDAQ:CSII) On Your Watch List?

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings released: US$0.35 loss per share (vs US$0.80 loss in FY 2020)

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 28%?

Is Now The Time To Look At Buying Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon Catheters

Cardiovascular Systems, Inc Announces Results from a Real-World Optical Coherence Tomography

Independent Director recently bought US$52k worth of stock

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fourth Quarter Ending June 30, 2021

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.085 loss in 3Q 2020)

We're Interested To See How Cardiovascular Systems (NASDAQ:CSII) Uses Its Cash Hoard To Grow

Cardiovascular Systems, Inc. Announces First Uses of WIRION® Embolic Protection System

Should You Take Comfort From Insider Transactions At Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Cardiovascular Systems (NASDAQ:CSII) Shareholders Have Enjoyed A Whopping 399% Share Price Gain

First Patient in Europe Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

Earnings beat expectations, revenue disappoints

Second quarter 2021 earnings released: US$0.001 loss per share (vs US$0.10 loss in 2Q 2020)

Cardiovascular Systems misses on revenue

Cardiovascular Systems, Inc. Announces Partnership with Chansu Vascular Techologies, Llc to Develop New Drug-Coated Balloon Technology

Cardiovascular Systems, Inc. Elects Sachin Jain as a Class II Director

New 90-day high: US$46.79

Cardiovascular Systems, Inc. to Report Q2, 2021 Results on Feb 03, 2021

New 90-day high: US$44.30

New 90-day high: US$39.84

Need To Know: Cardiovascular Systems, Inc. (NASDAQ:CSII) Insiders Have Been Selling Shares

Analysts update estimates

Cardiovascular Systems, Inc. 2021 Q1 - Results - Earnings Call Presentation

Revenue beats expectations, earnings disappoint

First quarter 2021 earnings released: US$0.054 loss per share

Cardiovascular Systems to Present Data from Large Coronary Orbital Atherectomy Study at the TCT Connect 2020 Conference

New 90-day high: US$39.35

Cardiovascular Systems Inc. signed a definitive agreement to acquire Replidyne, Inc. (NasdaqGM: RDYN) in a reverse merger transaction.

New 90-day high - US$34.99